AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25946305
Drug: Light shoes
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light shoes (352 ± 18.4 g)
Trial: 25946305
Drug: Heavy shoes
RxNorm normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heavy shoes (637 ± 17.7 g)
Trial: 23911013
Drug: Dapagliflozin 2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 2.5, 5, or 10 mg/day
Trial: 23631622
Drug: Psychiatric-Psychodynamic Treatment
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychiatric-Psychodynamic Treatment
Trial: 17064498
Drug: Thrombolytic agents
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic agents (urokinase or rt-PA) for massive and sub-massive PTE
Trial: 17064498
Drug: Anticoagulant agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant agents (IV infusion of unfractioned heparin or subcutaneous low-molecular-weight heparin) for non-massive PTE
Trial: 11036119
Drug: Troponin T
RxNorm normalized name: Troponin T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troponin T levels <0.06 microg/L
Trial: 11036119
Drug: Troponin T
RxNorm normalized name: Troponin T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troponin T levels 0.06 to 0.59 microg/L
Trial: 11036119
Drug: Troponin T
RxNorm normalized name: Troponin T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troponin T levels ≥0.60 microg/L
Trial: 11036119
Drug: C-reactive protein
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-reactive protein levels <2 mg/L
Trial: 11036119
Drug: C-reactive protein
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-reactive protein levels 2 to 10 mg/L
Trial: 11036119
Drug: C-reactive protein
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-reactive protein levels >10 mg/L
Trial: 11036119
Drug: Fibrinogen levels
RxNorm normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen levels <3.4 g/L
Trial: 11036119
Drug: Fibrinogen levels
RxNorm normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen levels 3.4 to 3.9 g/L
Trial: 11036119
Drug: Fibrinogen levels
RxNorm normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen levels ≥4.0 g/L
Trial: 7661066
Drug: Amiodarone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone treatment (800 mg/day for 2 weeks, then 400 mg/day thereafter)
Trial: 2748528
Drug: Adinazolam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adinazolam (10 to 60 mg daily, divided doses)
Trial: 862331
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of antidiuretic hormone at a low rate for 1 hr
Trial: 862331
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of antidiuretic hormone
Trial: 27353245
Drug: Extended-release methylphenidate
RxNorm normalized name: methylphenidate Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release methylphenidate (Ritalin® LA at a dose of 0.6 mg/kg)
Trial: 21145618
Drug: ABT‐874 (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT‐874 (dosage not specified)
Trial: 18940114
Drug: 0.125% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% bupivacaine 1 ml/kg with tramadol 1 mg/kg body weight
Trial: 18940114
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine 1 ml/kg body weight
Trial: 14584858
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy using an expanded polytetrafluoroethylene (ePTFE) membrane and demineralized freeze-dried bone allograft (DFDBA)
Trial: 11103236
Drug: Sequential methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sequential methotrexate and 5‐fluorouracil
Trial: 9058218
Drug: Intravenous milrinone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous milrinone, 50 micrograms/kg loading dose over 20 minutes followed by 0.5 microgram/kg/min infusion
Trial: 9058218
Drug: Open-label milrinone
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open-label milrinone administered after initial failure to wean from bypass
Trial: 8412049
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium 6 mg
Trial: 31377895
Drug: Vaginal laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal laser treatment (3 treatments administered 4 weeks apart)
Trial: 29546832
Drug: TA‐65 (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TA‐65 (16 mg daily for 12 weeks)
Trial: 22431716
Drug: Imiquimod, 5%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod, 5%, cream 5 d/wk for 3 months
Trial: 22431716
Drug: Imiquimod, 5%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod, 5%, cream 5 d/wk for 3 months plus tazarotene, 0.1%, gel 2 d/wk for 3 months
Trial: 18577931
Drug: Nifedipine in
RxNorm normalized name: nifedipine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine in combination with haloperidol
Trial: 15854633
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol (400 mug)
Trial: 11793395
Drug: Wa x
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wa x UK vaccine (P1A[8],G6); single oral dose;
Trial: 11793395
Drug: Wa x
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wa x (DS-1 x UK) vaccine (P1A[8],G2); single oral dose;
Trial: 10890259
Drug: Cefdinir 600
RxNorm normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefdinir 600 mg QD
Trial: 10890259
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V 250 mg QID
Trial: 7580360
Drug: Aprotinin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (2 million KIU IV at induction of anesthesia and 2 million KIU added to the extracorporeal circuit, followed by infusion of 500 thousand KIU/h during surgery)
Trial: 7580360
Drug: Epsilon-aminocaproic acid
RxNorm normalized name: Epsilon-Aminocaproic acid
DrugBank: Aminocaproic acid (DB00513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epsilon-aminocaproic acid (10 g IV at induction of anesthesia, followed by infusion of 2 g/h for 5 hours)
Trial: 7580360
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (10 mg/kg IV within 30 minutes after induction of anesthesia, followed by infusion of 1 mg/kg per hour for 10 hours)
Trial: 7580360
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no antifibrinolytic therapy)
Trial: 6370748
Drug: 0.1% Ro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% Ro 12‐7024 ointment
Trial: 27213795
Drug: Gliatilin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliatilin (1000 mg/4ml, 12-15 doses intravenously, then 1 capsule b.i.d. for 4 months orally)
Trial: 27213795
Drug: Standard neuroprotective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard neuroprotective therapy (not specified)
Trial: 19672055
Drug: Structured written
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured written and oral information about asthma and asthma medication, and asthma diary
Trial: 18576945
Drug: Adjuvanted vaccine
RxNorm normalized name: PIKA-adjuvanted vaccine composition
DrugBank: PIKA rabies vaccine (DB17963)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted vaccine (1.9, 3.8, 7.5, or 15 microg of hemagglutinin)
Trial: 18576945
Drug: Adjuvanted vaccine
RxNorm normalized name: PIKA-adjuvanted vaccine composition
DrugBank: PIKA rabies vaccine (DB17963)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted vaccine (higher doses)
Trial: 18576945
Drug: Non-adjuvanted vaccine
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted vaccine (7.5 microg of hemagglutinin)
Trial: 11989073
Drug: Intensive follow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive follow up (40 patients), controlled every 2 months with physical examination and lipid profile, diet and exercise enhancement, and statin dose adjustment.
Trial: 7794578
Drug: Diltiazem OD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem OD ER 240 mg
Trial: 7794578
Drug: Diltiazem OD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem OD ER 540 mg
Trial: 7794578
Drug: Diltiazem OD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem OD ER 360 mg
Trial: 7794578
Drug: Diltiazem OD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem OD ER 240 mg and above
Trial: 7000264
Drug: sulphinpyrazone 200
RxNorm normalized name: Sulphinpyrazone
DrugBank: Sulfinpyrazone (DB01138)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sulphinpyrazone 200 mg four times daily
Trial: 30113933
Drug: Suprachoroidal injection
RxNorm normalized name: NIACINAMIDE 5 g in 100 g SUPRACHOROIDAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprachoroidal injection of CLS-TA 4.0 mg
Trial: 30113933
Drug: Suprachoroidal injection
RxNorm normalized name: NIACINAMIDE 5 g in 100 g SUPRACHOROIDAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprachoroidal injection of CLS-TA 0.8 mg
Trial: 27862339
Drug: Cooling compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooling compound (CC) lotion applied twice daily for 4 weeks
Trial: 27862339
Drug: Cooling compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooling compound (CC) lotion
Trial: 22561365
Drug: Adenovirus serotype
RxNorm normalized name: Human Adenovirus Serotype 4 Strain Cl-68578
DrugBank: Human adenovirus e serotype 4 strain cl-68578 antigen (DB14409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenovirus serotype 5 (Ad5)‐vectored HIV vaccine
Trial: 21203519
Drug: Open-label placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label placebo pills (inert substance, like sugar pills)
Trial: 21203519
Drug: Open-label placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label placebo pills
Trial: 16320346
Drug: Raloxifene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (60 mg/day) plus elemental calcium (1,200 mg/day)
Trial: 12856761
Drug: Object of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Object of My Affection (treatment group)
Trial: 7989461
Drug: Pamidronate (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (150 mg/day)
Trial: 3053570
Drug: Spiramycin 2
RxNorm normalized name: spiramycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spiramycin 2 g orally daily
Trial: 3053570
Drug: Erythromycin 2
RxNorm normalized name: erythromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 2 g orally daily
Trial: 27622692
Drug: Denosumab 60
RxNorm normalized name: denosumab 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab 60 mg (two injections at baseline and after 6 months, n=10)
Trial: 27622692
Drug: Denosumab 60
RxNorm normalized name: denosumab 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab 60 mg (n=10)
Trial: 27622692
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (n=14)
Trial: 23899063
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with doxorubicin and paclitaxel
Trial: 20070351
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg once daily (N = 528)
Trial: 20070351
Drug: Metformin 1000
RxNorm normalized name: metformin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1000 mg twice daily (N = 522)
Trial: 18760583
Drug: TIO 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIO 18 microg once-daily (8 am) + FOR 12 microg (8 pm)
Trial: 18760583
Drug: FOR 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOR 12 microg twice-daily (8 am and 8 pm) + TIO 18 microg (8 pm)
Trial: 18760583
Drug: Single-drug treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-drug treatments
Trial: 18760583
Drug: Tr4 (TIO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tr4 (TIO 18 microg (8 am) + FOR 12 microg twice-daily (8 am and 8 pm))
Trial: 18760583
Drug: Tr5 (FOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tr5 (FOR 12 microg twice-daily (8 am and 8 pm) + TIO 18 microg (8 pm))
Trial: 12673696
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy regimens incorporating gemcitabine and paclitaxel with a platinum complex, with or without ifosfamide or doxorubicin
Trial: 12673696
Drug: Standard single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard single agents (methotrexate, doxorubicin, mitomycin, ifosfamide, vinblastine, cisplatin)
Trial: 6364688
Drug: i.m. injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.m. injection of 15‐methyl PGF2 alpha, 0.25 mg every second hour
Trial: 6364688
Drug: 16‐phenoxy‐omega‐17,18,19,20‐tetranor PGE2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16‐phenoxy‐omega‐17,18,19,20‐tetranor PGE2 methyl sulfonyl‐amide, 0.5 mg every fourth hour
Trial: 27191923
Drug: Remifentanil (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (target concentration: young 3 ng/ml; old 2 ng/ml)
Trial: 27191923
Drug: Morphine (dose:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (dose: young 0.1 mg/kg; old 0.07 mg/kg)
Trial: 22200383
Drug: Active US
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active US therapy (20% duty cycle, 1MHz, average temporal intensity: 0.2W/cm(2), therapeutic dose: 112.5J/cm(2))
Trial: 22200383
Drug: Sham US
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham US therapy (no sound-head crystal)
Trial: 21047602
Drug: 3 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 × 1 ml Orthovisc(®) hyaluronic acid injections
Trial: 21047602
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml single dose Orthovisc(®) hyaluronic acid injections
Trial: 21047602
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml single dose Orthovisc(®) hyaluronic acid injections
Trial: 21047602
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml single dose Orthovisc(®) hyaluronic acid injections
Trial: 17685257
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with irinotecan + 5-FU + leucovorin
Trial: 11856774
Drug: SYNSORB Pk
RxNorm normalized name: Synsorb Pk
DrugBank: TAK-751S (DB06432)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYNSORB Pk treatment (n = 19)
Trial: 7702016
Drug: Intravenous infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusions of pure fat or carbohydrate (2092 kJ)
Trial: 7702016
Drug: Intragastric infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intragastric infusions of fat or carbohydrate (2092 kJ)
Trial: 7702016
Drug: Slow intragastric
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow intragastric infusions of fat
Trial: 7702016
Drug: Slow intragastric
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow intragastric infusions of carbohydrate
Trial: 30079951
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (200 mg of ferrous fumarate weekly for 3 months)
Trial: 26151734
Drug: Sesamin 200
RxNorm normalized name: SESAMIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sesamin 200 mg/day
Trial: 23640622
Drug: Standard dialysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dialysate sodium concentration (138 mmol/L)
Trial: 20884297
Drug: HBVaxPro monovalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBVaxPro monovalent hepatitis B vaccine
Trial: 20884297
Drug: Engerix B
RxNorm normalized name: Engerix-B
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engerix B monovalent hepatitis B vaccine
Trial: 15087038
Drug: Chemotherapy +
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy + Reduced Glutathione (GSH)
Trial: 20858149
Drug: Orlistat (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (120 mg three times a day)
Trial: 7759671
Drug: Deep pressure/touch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep pressure/touch therapies
Trial: 7759671
Drug: Stress‐challenge treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stress‐challenge treatments
Trial: 7759671
Drug: Confrontational scare
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Confrontational scare treatments
Trial: 2496000
Drug: Cimetidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (400 mg b.i.d)
Trial: 31173130
Drug: Deep learning
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep learning model (HeadXNet) augmentation
Trial: 26666596
Drug: Diet and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet and exercise treatment for 3-6 months to reduce body weight by >5%
Trial: 23682110
Drug: Macitentan (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macitentan (10 mg once daily)
Trial: 21802649
Drug: 0.6 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 g/kg (high dose)
Trial: 21802649
Drug: 0.4 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 g/kg (low dose)
Trial: 21802649
Drug: 0 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g/kg (placebo)
Trial: 21802649
Drug: Alcohol (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (all doses)
Trial: 16960474
Drug: Intrathecal triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal triamcinolone acetonide (6 injections every third day)
Trial: 9161943
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oral vitamin K1 supplementation per week for 4 weeks
Trial: 7910126
Drug: Khat (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Khat (0.8 mg/kg body weight)
Trial: 31813317
Drug: Videoconference administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Videoconference administration of MoCA
Trial: 31813317
Drug: Face-to-face administration
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face administration of MoCA
Trial: 29871369
Drug: Lower one-third
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower one-third joint technique (group L)
Trial: 27271500
Drug: SpeechEasy® device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SpeechEasy® device used daily for 6 months
Trial: 22487170
Drug: Daily physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily physical education (5 × 45 min/week) and adapted motor training if needed
Trial: 20007734
Drug: Nabilone (0.5-1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabilone (0.5-1.0 mg before bedtime)
Trial: 20007734
Drug: Amitriptyline (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (10-20 mg before bedtime)
Trial: 11920267
Drug: Oral fludarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fludarabine phosphate on a full stomach
Trial: 11920267
Drug: Oral fludarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fludarabine phosphate on a fasted stomach
Trial: 9439551
Drug: Leucine infusion
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine infusion
Trial: 3661609
Drug: Sucralfate (Carafate)
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucralfate (Carafate) 1 g
Trial: 3661609
Drug: Cimetidine (Tagamet)
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine (Tagamet) 300 mg
Trial: 3661609
Drug: Placebo 1
RxNorm normalized name: placebo 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 g
Trial: 11466599
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment (n=46)
Trial: 11466599
Drug: Psychodynamic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychodynamic treatment (n=52)